;PMID: 1364175
;source_file_1768.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:43..137] = [t:43..137]
;2)section:[e:141..161] = [t:141..161]
;3)section:[e:165..207] = [t:165..207]
;4)section:[e:211..270] = [t:211..270]
;5)sentence:[e:274..442] = [t:274..442]
;6)sentence:[e:443..549] = [t:443..549]
;7)sentence:[e:550..692] = [t:550..692]
;8)sentence:[e:693..772] = [t:693..772]
;9)sentence:[e:773..886] = [t:773..886]
;10)sentence:[e:887..1085] = [t:887..1085]
;11)section:[e:1089..1133] = [t:1089..1133]

;section 0 Span:0..37
;Rev Med Chil. 1992 May;120(5):539-44.
(SEC
  (FRAG (NNP:[0..3] Rev) (NNP:[4..7] Med) (NNP:[8..12] Chil) (.:[12..13] .)
        (CD:[14..18] 1992) (NNP:[19..22] May) (CD:[22..27] ;120-LRB-)
        (CD:[27..28] 5) (-RRB-:[28..29] -RRB-) (::[29..30] :) (CD:[30..33] 539)
        (HYPH:[33..34] -) (CD:[34..36] 44) (.:[36..37] .)))

;sentence 1 Span:43..137
;[H2 antagonists as inhibitors of cytochrome P-450 in rat liver: in vitro and
;in  vivo effects]
;[44..46]:substance:"H2"
;[47..58]:substance:"antagonists"
;[62..72]:substance:"inhibitors"
;[76..92]:cyp450:"cytochrome P-450"
(SENT
  (NP-HLN (-LRB-:[43..44] -LSB-)
    (NP
      (NP (NN:[44..46] H2) (NNS:[47..58] antagonists))
      (PP (IN:[59..61] as)
        (NP
          (NP (NNS:[62..72] inhibitors))
          (PP (IN:[73..75] of)
            (NP (NN:[76..86] cytochrome) (NN:[87..92] P-450)))
          (PP-LOC (IN:[93..95] in)
            (NP (NN:[96..99] rat) (NN:[100..105] liver))))))
    (::[105..106] :)
    (NP
      (NP
        (ADJP (FW:[107..109] in) (FW:[110..115] vitro))
        (NML-1 (-NONE-:[115..115] *P*)))
      (CC:[116..119] and)
      (NP
        (ADJP (FW:[120..122] in) (FW:[124..128] vivo))
        (NML-1 (NNS:[129..136] effects))))
    (-RRB-:[136..137] -RSB-)))

;section 2 Span:141..161
;[Article in Spanish]
(SEC
  (FRAG (-LRB-:[141..142] -LSB-) (NN:[142..149] Article) (IN:[150..152] in)
        (NN:[153..160] Spanish) (-RRB-:[160..161] -RSB-)))

;section 3 Span:165..207
;Carrasco M, Gaule C, Vega P, del Villar E.
(SEC
  (FRAG (NNP:[165..173] Carrasco) (NNP:[174..176] M,) (NNP:[177..182] Gaule)
        (NNP:[183..184] C) (,:[184..185] ,) (NNP:[186..190] Vega)
        (NNP:[191..193] P,) (NNP:[194..197] del) (NNP:[198..204] Villar)
        (NNP:[205..207] E.)))

;section 4 Span:211..270
;Servicio de Medicina Interna, Hospital Regional de Copiapo.
(SEC
  (FRAG (NNP:[211..219] Servicio) (IN:[220..222] de) (NNP:[223..231] Medicina)
        (NNP:[232..239] Interna) (,:[239..240] ,) (NNP:[241..249] Hospital)
        (NNP:[250..258] Regional) (NNP:[259..261] de) (NNP:[262..269] Copiapo)
        (.:[269..270] .)))

;sentence 5 Span:274..442
;Cytochrome P-50 is a well known participant in the metabolism of xenobiotics
;as  well as an activator or inactivator of hepatotoxic substances and
;carcinogenic  agents.
;[274..289]:cyp450:"Cytochrome P-50"
;[339..350]:substance:"xenobiotics"
;[366..375]:substance:"activator"
;[379..390]:substance:"inactivator"
;[406..416]:substance:"substances"
;[435..441]:substance:"agents"
(SENT
  (S
    (NP-SBJ (NN:[274..284] Cytochrome) (NN:[285..289] P-50))
    (VP (VBZ:[290..292] is)
      (NP-PRD
        (NP
          (NP (DT:[293..294] a)
            (ADJP (RB:[295..299] well) (VBN:[300..305] known))
            (NN:[306..317] participant))
          (PP (IN:[318..320] in)
            (NP
              (NP (DT:[321..324] the) (NN:[325..335] metabolism))
              (PP (IN:[336..338] of)
                (NP (NNS:[339..350] xenobiotics))))))
        (CONJP (RB:[351..353] as) (RB:[355..359] well) (IN:[360..362] as))
        (NP
          (NP (DT:[363..365] an) (NN:[366..375] activator) (CC:[376..378] or)
              (NN:[379..390] inactivator))
          (PP (IN:[391..393] of)
            (NP
              (NP (JJ:[394..405] hepatotoxic) (NNS:[406..416] substances))
              (CC:[417..420] and)
              (NP (JJ:[421..433] carcinogenic) (NNS:[435..441] agents)))))))
    (.:[441..442] .)))

;sentence 6 Span:443..549
;H2 antagonists, cimetidine, famotidine and ranitidine were used to  inhibit
;cytochrome P-450 in rat liver.
;[443..445]:substance:"H2"
;[446..457]:substance:"antagonists"
;[459..469]:substance:"cimetidine"
;[471..481]:substance:"famotidine"
;[486..496]:substance:"ranitidine"
;[519..535]:cyp450:"cytochrome P-450"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[443..445] H2) (NNS:[446..457] antagonists))
      (,:[457..458] ,)
      (NP (NN:[459..469] cimetidine) (,:[469..470] ,) (NN:[471..481] famotidine)
          (CC:[482..485] and) (NN:[486..496] ranitidine)))
    (VP (VBD:[497..501] were)
      (VP (VBN:[502..506] used)
        (NP-1 (-NONE-:[506..506] *))
        (S-PRP
          (NP-SBJ (-NONE-:[506..506] *))
          (VP (TO:[507..509] to)
            (VP (VB:[511..518] inhibit)
              (NP (NN:[519..529] cytochrome) (NN:[530..535] P-450))
              (PP-LOC (IN:[536..538] in)
                (NP (NN:[539..542] rat) (NN:[543..548] liver))))))))
    (.:[548..549] .)))

;sentence 7 Span:550..692
;After 200 mg cimetidine, 85% inhibition  of cytochrome P-450 in vitro and 50%
;in vivo were demonstrated through  demethylation of aminopyrine.
;[556..559]:quantitative-value:"200"
;[560..562]:quantitative-units:"mg"
;[563..573]:substance:"cimetidine"
;[575..578]:quantitative-value:"85%"
;[594..610]:cyp450:"cytochrome P-450"
;[624..627]:quantitative-value:"50%"
;[680..691]:substance:"aminopyrine"
(SENT
  (S
    (PP-TMP (IN:[550..555] After)
      (NP
        (NML (CD:[556..559] 200) (NN:[560..562] mg))
        (NN:[563..573] cimetidine)))
    (,:[573..574] ,)
    (NP-SBJ-2
      (NP
        (NP
          (NP
            (NML (CD:[575..577] 85) (NN:[577..578] %))
            (NN:[579..589] inhibition))
          (PP (IN:[591..593] of)
            (NP (NN:[594..604] cytochrome) (NN:[605..610] P-450))))
        (ADJP (FW:[611..613] in) (FW:[614..619] vitro)))
      (CC:[620..623] and)
      (NP
        (NP (CD:[624..626] 50) (NN:[626..627] %))
        (ADJP (FW:[628..630] in) (FW:[631..635] vivo))))
    (VP (VBD:[636..640] were)
      (VP (VBN:[641..653] demonstrated)
        (NP-2 (-NONE-:[653..653] *))
        (PP-MNR (IN:[654..661] through)
          (NP
            (NP (NN:[663..676] demethylation))
            (PP (IN:[677..679] of)
              (NP (NN:[680..691] aminopyrine)))))))
    (.:[691..692] .)))

;sentence 8 Span:693..772
;Inhibition was further confirmed by differential  absorption spectra (Type
;II).
(SENT
  (S
    (NP-SBJ-1 (NN:[693..703] Inhibition))
    (VP (VBD:[704..707] was)
      (ADVP (RBR:[708..715] further))
      (VP (VBN:[716..725] confirmed)
        (NP-1 (-NONE-:[725..725] *))
        (PP (IN:[726..728] by)
          (NP-LGS
            (NP (JJ:[729..741] differential) (NN:[743..753] absorption)
                (NNS:[754..761] spectra))
            (PRN (-LRB-:[762..763] -LRB-)
              (NP (NN:[763..767] Type) (CD:[768..770] II))
              (-RRB-:[770..771] -RRB-))))))
    (.:[771..772] .)))

;sentence 9 Span:773..886
;The percentage inhibition obtained with famotidine  or ranitidine were lower
;than those obtained with cimetidine.
;[813..823]:substance:"famotidine"
;[828..838]:substance:"ranitidine"
;[875..885]:substance:"cimetidine"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[773..776] The) (NN:[777..787] percentage)
          (NN:[788..798] inhibition))
      (VP (VBN:[799..807] obtained)
        (NP (-NONE-:[807..807] *))
        (PP-MNR (IN:[808..812] with)
          (NP (NN:[813..823] famotidine) (CC:[825..827] or)
              (NN:[828..838] ranitidine)))))
    (VP (VBD:[839..843] were)
      (ADJP-PRD
        (ADJP (JJR:[844..849] lower))
        (PP (IN:[850..854] than)
          (NP
            (NP (DT:[855..860] those))
            (VP (VBN:[861..869] obtained)
              (NP (-NONE-:[869..869] *))
              (PP-MNR (IN:[870..874] with)
                (NP (NN:[875..885] cimetidine))))))))
    (.:[885..886] .)))

;sentence 10 Span:887..1085
;Inhibition of the  microsomal oxidative system by cimetidine could lead to
;decreased production of  superoxide radicals and protection against damage
;induced by toxic agents  activated in the liver.
;[937..947]:substance:"cimetidine"
;[987..1006]:substance:"superoxide radicals"
;[1054..1060]:substance:"agents"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[887..897] Inhibition))
      (PP (IN:[898..900] of)
        (NP (DT:[901..904] the) (JJ:[906..916] microsomal)
            (JJ:[917..926] oxidative) (NN:[927..933] system)))
      (PP (IN:[934..936] by)
        (NP (NN:[937..947] cimetidine))))
    (VP (MD:[948..953] could)
      (VP (VB:[954..958] lead)
        (PP-CLR (TO:[959..961] to)
          (NP
            (NP
              (NP (VBN:[962..971] decreased) (NN:[972..982] production))
              (PP (IN:[983..985] of)
                (NP (NN:[987..997] superoxide) (NNS:[998..1006] radicals))))
            (CC:[1007..1010] and)
            (NP
              (NP (NN:[1011..1021] protection))
              (PP (IN:[1022..1029] against)
                (NP
                  (NP (NN:[1030..1036] damage))
                  (VP (VBN:[1037..1044] induced)
                    (NP (-NONE-:[1044..1044] *))
                    (PP (IN:[1045..1047] by)
                      (NP-LGS
                        (NP (JJ:[1048..1053] toxic) (NNS:[1054..1060] agents))
                        (VP (VBN:[1062..1071] activated)
                          (NP (-NONE-:[1071..1071] *))
                          (PP-LOC (IN:[1072..1074] in)
                            (NP (DT:[1075..1078] the) (NN:[1079..1084] liver))))))))))))))
    (.:[1084..1085] .)))

;section 11 Span:1089..1133
;PMID: 1364175 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1089..1093] PMID) (::[1093..1094] :) (CD:[1095..1102] 1364175)
        (NN:[1103..1104] -LSB-) (NNP:[1104..1110] PubMed) (::[1111..1112] -)
        (NN:[1113..1120] indexed) (IN:[1121..1124] for)
        (NNP:[1125..1133] MEDLINE-RSB-)))
